[Relevance of posttransplant HLA-II antibodies production on long-term survival of renal allograft].
OBJECTIVE
To evaluate the clinic relevance of anti-HLA-II antibodies on allograft long-term survival.


METHODS
Perioperative sera of 118 cadaveric kidney recipients were tested by ELISA for anti-HLA-II antibodies in our prospective cohort study. All recipients who divided into different groups according to HLA antibody production were followed-up.


RESULTS
(1) Anti-HLA-II antibody-positive recipients were associated with significantly lower graft survival (78.6% vs 84.4%; 71.4% vs 80.0%; P = 0.002) and death-censored graft survival (85.7% vs 92.2%; 82.1% vs 90.0%; P = 0.003) at 3 and 4 years compared to antibody-negative recipients. (2) Anti-HLA-II antibody-positive recipients were associated with a significantly increased risk for decline in renal function at 3 and 4 years (39.3% vs 33.3%; 46.4% vs 38.9%, P = 0.001). (3) There was statistically non-significance difference in late-acute rejection rate between two groups (10.7% vs 13.3%, P > 0.05).


CONCLUSIONS
Posttransplant HLA-II antibodies perhaps are one of the most important influential facts on allograft long-term survival and could be used to predict the prognosis of allograft.
Liu
Zhi-hong
ZH
Department of Transplant-Urology, Shanghai First People's Hospital, Jiaotong Univisity, Shanghai 200080, China. drzhihongliu2000@yahoo.com.cn
Shen
Bing
B
Tan
Jian-ming
JM
Ding
Yan-de
YD
D000328:Adult; D000917:Antibody Formation; D001323:Autoantibodies / Q000276:immunology*; D002102:Cadaver; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival / Q000276:immunology*; D006681:HLA-D Antigens / Q000276:immunology*; D006801:Humans; D053208:Kaplan-Meier Estimate; D016030:Kidney Transplantation / Q000379:methods*; D008875:Middle Aged; D011184:Postoperative Period; D011446:Prospective Studies; D013997:Time Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous
D001323:Autoantibodies; D006681:HLA-D Antigens